Tevogen Bio (NASDAQ:TVGN) Sets New 52-Week Low – Should You Sell?

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) shares hit a new 52-week low during trading on Friday . The stock traded as low as $6.2175 and last traded at $10.76, with a volume of 58999 shares traded. The stock had previously closed at $7.7550.

Tevogen Bio News Summary

Here are the key news stories impacting Tevogen Bio this week:

• Positive Sentiment: Signed a non‑binding Letter of Intent to evaluate acquiring Apozeal Pharmaceutical, which could add an established generics platform (11 FDA‑approved ANDAs plus pipeline) and accelerate revenue generation if consummated. Read More.
• Positive Sentiment: Management disclosed ongoing strategic initiatives including potential acquisitions to expand immunotherapy and AI capabilities; management estimates combined targets could exceed $50M in annual revenue, signaling a shift toward predictable, revenue‑generating subsidiaries. Read More.
• Neutral Sentiment: CEO letter reiterates the company’s disciplined growth and affordability mission, restating strategy but offering no finalized transactions; useful context but not an immediate earnings driver. Read More.
• Neutral Sentiment: Multiple intraday LULD pauses and a prior “news pending” halt reflect high volatility and information flow — this can amplify moves in either direction until clarity arrives.
• Negative Sentiment: Company is implementing a 1-for-50 reverse stock split, effective March 6 — reverse splits often trigger short‑term selling, reduce float granularity, and can signal balance‑sheet or listing concerns to some investors. Read More.
• Negative Sentiment: Analyst sentiment has softened with at least one firm lowering expectations for TVGN’s share price, which may pressure sentiment while deal outcomes remain uncertain. Read More.
• Negative Sentiment: All acquisition announcements are non‑binding and forward‑looking; the company warns deals may not close and additional capital could be required — investor skepticism over execution and timing is a likely headwind. Read More.

Analyst Upgrades and Downgrades

A number of research firms recently commented on TVGN. D. Boral Capital lowered shares of Tevogen Bio from a “buy” rating to a “hold” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $100.00.

Tevogen Bio Stock Performance

The company has a market capitalization of $29.02 million, a PE ratio of -0.77 and a beta of -0.76. The stock has a 50 day moving average price of $15.01 and a two-hundred day moving average price of $25.86.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of TVGN. Deutsche Bank AG lifted its stake in shares of Tevogen Bio by 304.1% in the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after purchasing an additional 130,738 shares during the last quarter. Bridgeway Capital Management LLC increased its position in Tevogen Bio by 66.7% during the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after buying an additional 33,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in Tevogen Bio by 126.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after buying an additional 152,572 shares in the last quarter.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.